Relay Therapeutics Hits Phase 3 Milestone in X-Chem Collaboration
RLAY has more than doubled off its 52-week low of $4.32 on light trading volume (0.3× avg).
Summary
Relay Therapeutics and X-Chem have reached a Phase 3 milestone in their collaboration, a positive development for the company's pipeline. This is the first report of this milestone, which could signal progress in a key program. The news follows a period of insider selling and an upsized ATM offering, but this milestone is a fresh, material update. Traders will want to understand the financial terms and which program advanced.
At the time of this announcement, RLAY was trading at $18.54 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.1B. The 52-week trading range was $4.32 to $21.27. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.